- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03862274
Examining Developmental Outcomes of Children Diagnosed With CLN2 Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
CLN2 disease is a predominantly late infantile form of neuronal ceroid lipofuscinosis and one of the many genetic isoforms of Batten disease. Mutations in the CLN2 gene are characterized by deficient lysosomal serine protease TPP1, an enzyme that metabolizes intracellular lysosomal storage materials. Accumulations of intracellular deposits occur over time and in many organs of individuals with CLN2 disease and lead to neurodegeneration and, eventually, death. CLN2 disease is an extremely rare genetic disease affecting around 1 per 200,000 live births. Symptoms emerge early in life typically between the ages of 2 and 4 years of age and include seizures, as well as loss of motor, language, and vision functioning. Development further declines in early childhood and by age 6 years, children with CLN2 are often unable to walk or sit unsupported and become blind. The progression of the disease is rapid with death typically occurring in mid-childhood between the ages of 10 and 15 years of age.
Recently, enzyme replacement therapy (ERT), cerliponase alfa, which is a recombinant form of human TPPI, was the first FDA-approved treatment to slow the progression of motor decline in children with CLN2. Cerliponase alfa is expected to restore TPP1 enzyme activity in the brain and alter neurodegeneration and disease progression. Animal models suggest promising treatment outcomes as cerliponase alfa significantly delayed the onset of clinical signs, preserved motor and cognitive function, and prolonged life. Initial results from a clinical trial further demonstrated that patients receiving cerliponase alfa had less motor declines, as measured by the CLN2 Clinical Rating Scale, compared to a natural history cohort. Despite these promising results, little is known about the trajectory of other developmental domains, including language, social-emotional, and adaptive functioning of children receiving cerliponase alfa. Likewise, the developmental trajectory of untreated patients with CLN2 is not well understood. Therefore, it is important to understand developmental outcomes and the progression of CLN2 in a natural history cohort in order to compare the effectiveness of treatment outcomes.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Jessica Scherr, PhD
- Phone Number: 614-355-7500
- Email: jessica.scherr@nationwidechildrens.org
Study Contact Backup
- Name: Emily de los Reyes, MD
- Phone Number: 614-722-4625
- Email: Emily.delosReyes@nationwidechildrens.org
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43205
- Nationwide Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients that have a TPP1 enzyme deficiency
- Patients have confirmed molecular diagnosis of pathogenic variants in the TPP1 gene
- Patients that are enrolled in post-marketing studies will be allowed to enroll into the current study
Exclusion Criteria:
- Patients without a diagnosis of CLN2 and deficiency of TPP1
- Patients that are currently enrolled as part of a larger multi-center clinical trial
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Other
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
CLN2 Natural History Control Group
Patients that have a TPP1 enzyme deficiency and/or confirmed molecular diagnosis of pathogenic variants in the TPP1 gene are eligible to participate if they are untreated or not receiving cerliponase alfa.
|
|
CLN2 Treatment Group
Patients that have a TPP1 enzyme deficiency and/or confirmed molecular diagnosis of pathogenic variants in the TPP1 gene are eligible to participate if they are receiving cerliponase alfa.
|
Patients that have a TPP1 enzyme deficiency and/or confirmed molecular diagnosis of pathogenic variants in the TPP1 gene are eligible to participate if they are receiving cerliponase alfa.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Visual Reception Skills on the Mullen Scales of Early Learning
Time Frame: up to 4 years
|
Changes in the Visual Reception subscale on the Mullen Scales of Early Learning will be assessed every 6 months.
Visual reception skills are a measure of visual processing and problem solving.
Raw scores will be used as a measure of visual receptions skills with scores ranging from 0 to 50.
Higher scores indicate more visual reception skills.
|
up to 4 years
|
Changes in Fine Motor Skills on the Mullen Scales of Early Learning
Time Frame: up to 4 years
|
Changes in the Fine Motor subscale on the Mullen Scales of Early Learning will be assessed every 6 months.
Fine motor skills are a measure of fine motor coordination.
Raw scores will be used as a measure of fine motor skills with scores ranging from 0 to 49.
Higher scores indicate more fine motor skills.
|
up to 4 years
|
Changes in Receptive Language Skills on the Mullen Scales of Early Learning
Time Frame: up to 4 years
|
Changes in the Receptive Language subscale on the Mullen Scales of Early Learning will be assessed every 6 months.
Receptive language skills are a measure of the understanding of language.
Raw scores will be used as a measure of receptive language skills with scores ranging from 0 to 48.
Higher scores indicate more receptive language skills.
|
up to 4 years
|
Changes in Expressive Language Skills on the Mullen Scales of Early Learning
Time Frame: up to 4 years
|
Changes in the Expressive Language subscale on the Mullen Scales of Early Learning will be assessed every 6 months.
Expressive language skills are a measure of how an individual communicates.
Raw scores will be used as a measure of expressive language skills with scores ranging from 0 to 50.
Higher scores indicate more expressive language skills.
|
up to 4 years
|
Motor and Language Changes on the CLN2 disease rating scale
Time Frame: up to 4 years
|
Change in motor and language subscales of the CLN2 disease rating scale.
Ranges for scores are 0 to 6 with higher scores indicating more abilities in motor and language skill development.
|
up to 4 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Receptive Language Skills on the Preschool Language Scales
Time Frame: up to 4 years
|
Changes in the Receptive Language subscale on the Preschool Language Scales will be assessed every 6 months.
Receptive language skills are a measure of the understanding of language.
Raw scores will be used as a measure of receptive language skills with scores ranging from 0 to 65.
Higher scores indicate more receptive language skills.
|
up to 4 years
|
Changes in Expressive Language Skills on the Preschool Language Scales
Time Frame: up to 4 years
|
Changes in the Expressive Language subscale on the Preschool Language Scales will be assessed every 6 months.
Expressive language skills are a measure of how an individual communicates.
Raw scores will be used as a measure of expressive language skills with scores ranging from 0 to 67.
Higher scores indicate more expressive language skills.
|
up to 4 years
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Schulz A, Kohlschutter A, Mink J, Simonati A, Williams R. NCL diseases - clinical perspectives. Biochim Biophys Acta. 2013 Nov;1832(11):1801-6. doi: 10.1016/j.bbadis.2013.04.008. Epub 2013 Apr 17.
- Schulz A, Ajayi T, Specchio N, de Los Reyes E, Gissen P, Ballon D, Dyke JP, Cahan H, Slasor P, Jacoby D, Kohlschutter A; CLN2 Study Group. Study of Intraventricular Cerliponase Alfa for CLN2 Disease. N Engl J Med. 2018 May 17;378(20):1898-1907. doi: 10.1056/NEJMoa1712649. Epub 2018 Apr 24.
- Wisniewski KE, Zhong N, Philippart M. Pheno/genotypic correlations of neuronal ceroid lipofuscinoses. Neurology. 2001 Aug 28;57(4):576-81. doi: 10.1212/wnl.57.4.576.
- Worgall S, Kekatpure MV, Heier L, Ballon D, Dyke JP, Shungu D, Mao X, Kosofsky B, Kaplitt MG, Souweidane MM, Sondhi D, Hackett NR, Hollmann C, Crystal RG. Neurological deterioration in late infantile neuronal ceroid lipofuscinosis. Neurology. 2007 Aug 7;69(6):521-35. doi: 10.1212/01.wnl.0000267885.47092.40.
- Williams RE, Aberg L, Autti T, Goebel HH, Kohlschutter A, Lonnqvist T. Diagnosis of the neuronal ceroid lipofuscinoses: an update. Biochim Biophys Acta. 2006 Oct;1762(10):865-72. doi: 10.1016/j.bbadis.2006.07.001. Epub 2006 Jul 12.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB18-00464
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Batten Disease
-
Beyond Batten Disease FoundationTheranexusActive, not recruitingBatten DiseaseUnited States
-
Amicus TherapeuticsActive, not recruiting
-
Amicus TherapeuticsActive, not recruitingBatten Disease | CLN6United States
-
Emily de los ReyesRecruitingBatten Disease | CLN6United States
-
Weill Medical College of Cornell UniversityNathan's Battle FoundationCompletedBatten Disease | Late-Infantile Neuronal Ceroid Lipfuscinosis
-
Universitätsklinikum Hamburg-EppendorfRecruitingBatten Disease | Neuronal Ceroid Lipofuscinosis | CLN1 Disease | CLN2 Disease | CLN3 Disease | CLN4 Disease | CLN5 Disease | CLN6 Disease | CLN7 Disease | CLN8 Disease | CLN10 Disease | CLN11 Disease | CLN12 Disease | CLN13 Disease | CLN14 DiseaseGermany
-
BioMarin PharmaceuticalCompletedBatten Disease | CLN2 Disease | Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 | Jansky-Bielschowsky DiseaseUnited States, Italy, Germany, United Kingdom
-
National Human Genome Research Institute (NHGRI)RecruitingDiabetes | Undiagnosed Diseases | Inherited Metabolic Disorders | Batten's Disease | Tay SachsUnited States
-
BioMarin PharmaceuticalCompletedBatten Disease | CLN2 Disease | Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 | Jansky-Bielschowsky Disease | CLN2 DisorderUnited States, Germany, Italy, United Kingdom
-
BioMarin PharmaceuticalCompletedBatten Disease | CLN2 Disease | Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 | Jansky-Bielschowsky Disease | CLN2 DisorderUnited States, Germany, Italy, United Kingdom
Clinical Trials on CLN2 Treatment
-
PfizerCompleted
-
PfizerCompleted
-
Chiesi Farmaceutici S.p.A.Completed
-
Gilead SciencesCompletedChronic Lymphocytic LeukemiaUnited States
-
JW PharmaceuticalCompletedHealthyKorea, Republic of
-
PfizerCompleted
-
AstraZenecaParexelCompleted
-
PfizerCompletedHealthy VolunteersUnited States
-
Assistance Publique - Hôpitaux de ParisRecruitingIntra-articular Fracture of the Mandibular CondyleFrance
-
New Mexico VA Healthcare SystemCompletedPost Traumatic Stress DisorderUnited States